Abstract. The major cause of death in colorectal cancer is related to liver metastasis. Although the metastatic process has been well studied, many aspects of the molecular genetic basis of metastasis remain unclear. Elucidation of the molecular nature of liver metastasis is urgent to improve the outcome of colorectal cancer. We analyzed the chronological gene expression profiles of 104 colorectal samples corresponding to oncogenic development including normal mucosa, localized and metastasized primary tumors, and liver metastatic lesions as fundamental samples using a custom cDNA microarray. The gene expression patterns in 104 samples were classified into four groups closely associated with their metastatic status, and the genes of each group appropriately reflected the metastatic process. To investigate the existence of metastatic potential in primary tumors using metastasis-related genes detected by chronological analysis, we performed a hierarchical cluster and supervised classification analysis of 28 independent primary tumors. Hierarchical cluster analysis segregated the tumors according to their final metastatic status, rather than their clinical stages, and the profile of metastasized primary tumors resembled one of a metastatic lesion apart from a primary lesion rather than one of a non-metastasized primary tumor. Using the supervised classification approach, the expression profile of these genes allowed the classification of tumors diagnosed as localized cancer into two classes, the localized and the metastasized class, according to their final metastatic status. The disease-free survival and overall survival were significantly longer in the localized class than the metastasized class. Chronological analysis of the gene expression profile provides a better understanding of the metastatic process. Our results suggest that the metastatic potential is already encoded in the primary tumor and is detectable by a gene expression profile, which allows the prediction of liver metastasis in patients diagnosed with localized tumors and also the design of new strategies for the treatment and diagnosis of colorectal cancer.
Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide and considerable progress has been made in identifying the mechanisms of tumorigenesis based on molecular and biological research (1) . The number of completely cured patients has increased because of improvements in screening technology and localized treatment; however, this has not resulted in major improvements in the prognosis of patients with advanced cancers. The major cause of death in patients with CRC is metastasis, particularly liver metastasis (2) . Despite the development of various treatment modalities, once a metastatic lesion is discovered, the outcome for the patient is unfavorable. Therefore, elucidation of the global nature of liver metastasis in CRC is clinically important (3) .
The phenomenon of cancer metastasis has been extensively studied morphologically and has been characterized as a complex, multistep process, and each step of this process is regulated by various changes on a genetic level (4) (5) (6) . Thus, to understand cancer metastasis, it is important to comprehensively analyze the alterations of the genes involved in this process (7, 8) . DNA microarray technology is an efficient approach to a wide range of applications in cancer research (9) . Gene expression profiling can identify biologically and clinically important subgroups of malignant tumors such as CRC (10) (11) (12) . Indeed, it is possible to mark the histopathological differentiation at a molecular level, and the analysis could help to explain the complexity of the disease process and can more accurately assess prognosis and distinct behavior.
Conventional diagnosis and surveillance have been performed by histopathological and clinical parameters such as the TNM stage and serum tumor markers such as the carcinoembryonic antigen (CEA). An elevated serum CEA level is regarded as a good indicator of metastatic disease and post-operative testing is recommended for the survey of recurrence, whereas ~30% of all CRC recurrences do not produce CEA (13) . Currently, the prediction of metastasis or recurrence is also achieved by molecular parameters that focus on individual candidate genes such as the vascular endothelial growth factor (VEGF) and deleted-in-colon carcinoma (DCC) genes. However, these molecular diagnoses are not always accurate in predicting metastasis in the individual patient, and have not yet been validated for use as a diagnostic tool applicable to clinical practice (14) . Thus, there has been a tremendous amount of effort to diagnose recurrent CRC in clinical practice.
Several investigators have reported that the gene expression profile makes it possible to predict the outcome including metastasis (15) (16) (17) . These reports suggest that the gene expression profile has the potential to be applied clinically for the diagnosis of metastasis, and that a more precise diagnosis of metastasis than the current one can be achieved based on a comprehensive analysis of each distinct step of metastasis at a molecular level.
The present study was designed to analyze the chronological changes in the gene expression profiles of 104 patients as the fundamental set using cDNA microarray (Colonochip), which was developed for the analysis of CRC (18) . We identified the gene expression profiles that reflected each step of cancer progression, including carcinogenesis, metastatic potential and metastatic colonization. To validate the predictability of metastasis by the gene expression profile in the bulk of primary tumors, we focused on the genes that correlated with the metastatic potential in the fundamental set. We then profiled the gene expression of 28 independent primary tumors that were diagnosed as localized or regional diseases at the time of surgery and investigated whether the expression profile in the primary tumors could determine their metastatic potential. Tissues from 12 normal colonic tissues, 12  stage I and 20 stage II primary tumors without metastasis  (stage I-LOC and stage II-LOC), 7 stage III and 19 stage IV  primary tumors with liver metastasis (stage III-MET and  stage IV-MET) , and 34 liver metastatic specimens (LIV) were obtained from February 1989 to August 2000 and analyzed as the fundamental sample set. The clinicopathological backgrounds of the patients are summarized in Table I . All samples were immediately frozen in liquid nitrogen after surgical resection and stored at -80˚C until further use. Each sample was examined histopathologically and all normal tissues were confirmed to be free of cancer. Samples were collected from patients who had given informed consent and the study was approved by the Ethics Committee of Osaka University.
Materials and methods

Tissue samples.
cDNA microarray, tissue preparation, hybridization and data processing. We used the cDNA microarray 'Colonochip' specifically designed for analyzing CRC. The reliability of Colonochip had been confirmed previously by comparison with the data obtained from two distinct assays: Reverse transcription-polymerase chain reaction (RT-PCR) and serial analysis of the gene expression (SAGE) database (18, 19) . Tissue preparation, hybridization, washing, scanning and image analysis were performed as described previously (18) . In each sample, the values of the Cy3/Cy5 ratio of each spot were log-transformed and normalized so that the median Cy3/Cy5 ratio of whole genes was 1.0. Genes with <85% valid data points in the sample sets were excluded from further analysis, and hence, 1,953 genes were selected at this stage.
Statistical analysis. We calculated the signal-to-noise (S2N) statistics to identify differentially expressed genes with regard to each class distinction [(for example, normal mucosa vs primary cancer and normal mucosa vs metastatic cancer) (Ì 0 -Ì 1 )/(Û 0 +Û 1 )]. The symbol Ì represents the mean and Û represents the standard deviation of expression for each class of each gene in the dataset. To compare these correlations to what would be expected by chance, permutation of the sample labels was performed and the S2N statistics in each permutation were calculated. One thousand global random permutations were used to build histograms. The assumption was made that these histograms were normally distributed. Based on these histograms, the z-score and significance levels were determined and then compared with the values obtained for the real dataset (20) . We defined genes with a 99 percentile set as significantly different.
Gene ontology analysis. GoMiner (http://discover.nci.nih.gov/ gominer/) was used to investigate the biological significance of a set of genes represented by the specific expression pattern during the progression of cancer metastasis (21) . We calculated whether the gene ontology (GO) category was enriched or depleted for each group of genes represented by the specific expression pattern with respect to what would have been expected by chance alone, using the two-sided Fisher's exact test. We focused our analysis on a GO term that had >10 associated genes in order to evaluate the significance of a GO term. Table I shows the clinicopathological backgrounds of these patients.
Hierarchical cluster analysis. To investigate whether the expression profile in the primary tumor reflected metastatic status, we analyzed the expression profiles of 92 tumors in the fundamental set, using 119 genes that were regarded as relevant to the metastatic potential by chronological analysis. Furthermore, the expression profiles of 120 tumors (adding the 92 tumors to the 28 independent tumors) were analyzed using the same genes. Hierarchical cluster analysis (HCA) was performed with Pearson's correlation coefficient as a similarity coefficient and the unweighted pair group method using arithmetic averages (UPGMA) as the clustering algorithm.
Classification analysis with independent samples. We applied the weighted vote method as the class predictor (20) . The prediction of a new sample is based on the 'weighted votes' of 119 informative genes. Each such gene g i votes for either LOC or MET, depending on whether its expression level x i in the sample is closer to Ì LOC or Ì MET (which denote, respectively, the mean expression levels of LOC and MET in the fundamental set). 
Results
The 1,953 genes were classified into four distinct groups according to the following expression patterns. Group A (A1 and A2) consisted of 369 genes that were differentially expressed during all tumorgenic stages; group B (B1 and B2) consisted of 119 genes that were differentially expressed in synchronously or metachronously metastasized tumors and liver metastasis; group C (C1 and C2) consisted of 430 genes that were differentially expressed in liver metastasis; group D consisted of 1,035 genes that were not characterized by the expression pattern at all steps of cancer development (Fig. 1) . The expression patterns of the genes of group A, B and C correlated with the phenomena of cancer progression in CRC; carcinogenesis, metastatic potential and metastatic Table I . Clinicopathological characteristics of the profiled cancer samples. 
LOC, localized primary tumor; MET, metastasized primary tumor.
colonization, respectively. The list of genes of group A, B or C are shown in Supplementary Table I, which is available on our website (http://www.dna-chip.co.jp/other/ other/ download_20060822.html).
Functional analysis based on GO was performed to translate the lists of differentially regulated genes in order to gain a better understanding of the underlying biological phenomenon. Table II shows the representative GO functional classes as upper-hierarchical terms in the final branch under the biological-process ontology with a significance of p<0.05 in each group, and all of the terms are shown in Supplementary  Fig. 1 , which is available on our website (http://www.dnachip.co.jp/other/other/download_20060822.html), based on the directed acyclic graph structure of the GO and their hierarchy.
Group A1 included genes related to DNA metabolism, cell cycle, and response to endogenous stimuli such as response to DNA damage. Response to external stimuli such as defense and immune responses were represented in group A2. Genes related to apoptosis, cell motility and response to external stimuli were included in group B. Group C included genes involved in signal transduction such as the intracellular signaling cascade and cell-cell signaling, defense response and response to stress.
To investigate whether the expression profile in the bulk of primary tumors reflected metastatic status, we analyzed the gene expression profiles of 92 tumors in the fundamental set. HCA of 92 CRCs using the 119 genes in group B, which were detected by chronological analysis as genes closely associated with metastatic potential, was performed, and the tumors were segregated into two major categories, each consisting of 44 and 48 tumors, respectively ( Fig. 2A) . The left cluster (non-metastatic cluster) was comprised of 28 LOC, 10 MET and 6 LIV, whereas the right cluster (metastatic cluster) was comprised of 4 LOC, 16MET and 28 LIV. These two clusters correlated significantly with the metastatic status of the tumors.
Next, we performed HCA of 120 tumors (92 fundamental tumors and 18 independent ones) (Fig. 2B) . The clustering pattern was robust against sample addition. For instance, the partitioning of the clusters and 92 fundamental tumors in the two sub-branches remained similar with little change.
As for the independent samples, 17 of the 18 stage II and III samples without metastasis belonged to the non-metastatic cluster despite of the clinical staging. Unexpectedly, all of the 10 stage II or III samples that metachronously developed liver metastasis although they had been diagnosed as localized or regional disease at the time of initial diagnosis belonged to the metastatic cluster. The expression profile of the independent samples was closely associated with the metastatic potential in the primary tumor rather than the histopathological staging. Line graphs represent the z-score calculated by permutation testing in each sample group at the stage of development. Group A (A1 and A2) consisted of 369 genes that were differentially expressed during the development of the carcinogenic process (A1, up-regulated genes; A2, down-regulated genes); group B (B1 and B2) consisted of 119 genes that were differentially expressed in localized tumors and metastasized tumors; group C (C1 and C2) consisted of 430 genes that were characterized by a differential expression pattern in liver metastasis.
We assessed the utility of these 119 genes to identify patients who would develop liver recurrence after surgery. The expression of these 119 genes was used to build a weighted vote-based classifier that could predict liver metastasis at the time of surgery. We applied this classifier to the 28 independent samples. Eighteen and 10 patients were assigned to the localized signature and metastasized signature, respectively. Seventeen of the 18 (94.4%) patients assigned to the localized signature did not relapse at least 47 months after surgery, and 9 of the 10 (90%) patients assigned to the Table II . Functional gene classes demonstrating significant differential expression in each group. 
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a Total number of genes represented in each group corresponding to a specific gene ontology term, b p-value in the X group (X=A, B or C).
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metastasized signature recurred to liver metastasis after surgery (Table III) . The successful prediction of liver metastasis could be shown in the independent set of tumors.
To assess the association between class assigned by gene expression profile and survival, we plotted Kaplan-Meier survival curves of 28 patients in the independent set (Fig. 3A and B). A significant difference was observed in the diseasefree survival (p<0.0001) and overall survival (p=0.0065) of patients between the localized and metastasized signature.
Discussion
The gene expression profile using DNA microarray is a promising approach to investigate the molecular complexity of cancer. Several studies have reported the usefulness of this technique such as the gene identification related to metastasis and possible prediction of metastasis in various cancers (16, 17) . However, these studies simply compared the gene expression profile of tumors between partial stages and did not directly address the metastatic process. To elucidate the phenomenon of metastasis more accurately, it is critical to analyze comprehensively the process of gradual change in cancer progression. Thus, we analyzed the gene expression profiles of 104 samples at four time points in cancer development; normal colon, localized and metastasized primary Table III . The predictive diagnosis of liver metastasis in the independent samples. ----------------------------------------------Figure 3 . Kaplan-Meier plot of disease-free (A) and overall (B) survival of patients with the localized and metastasized signature. (A) Disease-free survival curves of patients with the localized signature were also higher than those of patients with the metastasized signature (log-rank test, p<0.0001). (B) Overall survival curves of patients with the localized signature were higher than those of patients with the metastasized signature (log-rank test, p=0.0065).
tumor and liver metastasis. These analyses indicate that each step of cancer progression can be characterized by a gene expression profile.
The expression pattern of group A is considered to be associated with the promotion of carcinogenesis in CRC. This group contained a significantly high proportion of genes with functions relevant to carcinogenesis such as cell proliferation and response to external and endogenous stimuli, and any imbalance in these functions initiates colorectal carcinogenesis. If these genes were expressed on the cell surface or secreted, this could be detected by easier methods such as immunohistochemical analysis and be applicable clinically as candidate diagnostic markers for the early detection of CRC (cellular-component, data not shown).
The expression of the genes represented in group B is significantly different in the primary tumor with or without metastasis, which directly reflects the event of metastasis itself. The loss or acquisition of this function in this group was closely relevant to the liver metastatic potential in colorectal cancer. This group contained a significantly high proportion of genes with functions relevant to the process of metastasis such as cell motility and apoptosis. The acquisition of cell motility is essential for the invasion of interstitial tissue and lymphatic or vascular vessel walls and the survival of cancer cells against immune and non-immune defenses while escape from apoptosis allows cancer cells to arrest a secondary organ apart from the primary lesion. Genes such as DCC and GDP dissociation inhibitor 2 (GDI2), which are referred as relevant to metastasis, are included in group B. For example, DCC is a putative tumor suppressor gene, which has considerable homology to neural cell adhesion molecules and may be involved in the regulation of cell-tocell or cell-to-substrate interactions with a potential functional role in the control of cell growth and the development of metastasis (22) (23) (24) . Various studies reported that DCC is a predictor of distant metastasis and prognosis in colorectal cancer (24) (25) (26) . Furthermore, DCC expression has been shown recently to predict clinical outcome to fluorouracilbased chemotherapy (27) . Other studies have reported that the DCC gene product induced apoptosis through a caspasedependent mechanism (28, 29) . In another study, GDI2 was identified as a metastasis-suppressor gene (30) . GDI2 is an inhibitor of guanine nucleotide dissociation from RHO and RAC proteins, strongly inhibiting GDP/GTP exchange reaction. GDI2, RHO and RAC also modulate signal transduction such as the ERK, JNK and p38 MAPK pathways, three arms of which are involved in invasion, growth-factorreceptor signaling, the mitogen-activated protein kinase pathway, cell-cell communication and transcription, which are the main factors involved in the induction of liver metastasis (31, 32) .
The expression pattern of group C is closely associated with the colonization and maintenance of metastasis, which is the outgrowth of cancer cells after arrival at a secondary organ. Functional analysis indicated that metastatic colonization occurs as a result of the cancer cells' modification following interaction with the surrounding environment in the liver. Other investigators also reported similar results (16, 33, 34) . Nishizuka et al (34) reported that cytokines produced by glial cells in vivo may contribute in a paracrine manner to the development of brain metastases from breast cancer cells. Metastatic colonization differs from growth in the primary lesion by its requirement for angiogenesis, and changes in the local microenvironment in metastatic lesions and stressful conditions. The requirement for various growth factors and chemokines, the cell-cell or cell-extracellular matrix interaction and the activity of intracellular signaling pathways regulated by various stimuli and interactions could have considerable influence upon not only the initiation but also the maintenance of metastatic colonization (35, 36) . For example, MAP3K4 and ERK1, which are differentially expressed in the metastatic tumor, stimulate the p38 and JNK MAPK pathway, and the MAPK-ERK pathway, respectively. Reduced JNK and p38 signals facilitate metastatic colonization by preventing apoptosis induced by the stress of a foreign environment (37) . Numerous reports have linked the activation of ERK1 with metastasis, motility and invasion, and angiogenesis (38, 39) . This result suggests that the crosstalk between signaling pathways, which were represented in the MAPK pathway, such as the ERK, p38 and JNK pathways, are linked closely within the cancer cells and interstitial tissue to adhesion, motility, proliferation, angiogenesis and apoptosis in metastatic lesions, which represents the final step in cancer development. These genes might be candidate markers of metastasis and could be suitable targets for the treatment of metastatic disease.
Chronological analysis allowed us to clarify each step of cancer progression, carcinogenesis to metastasis, at the molecular level. In particular, we were successful in separating metastasis into the acquisition of metastatic potential (group B) and the initiation and maintenance of metastatic colonization (group C). Does the gene expression pattern correlate with the metastatic potential (such as that represented in group B) already present in the bulk of the primary tumor and detectable at the time of initial diagnosis? The conventional hypothesis about metastasis is that acquisition of the metastatic phenotype may occur late in tumor progression. Primary CRC cells arise from the normal colorectal epithelium through oncogenic mutations. The occasional cancer cells possessing metastatic ability in the primary tumor population can accumulate additional genetic changes that mediate metastasis to the liver. Thus, it has been hypothesized that primary tumors have gene expression profiles in which only a fraction of the metastatic potential exists. However, some groups have challenged this hypothesis (16, 17) . Ramaswamy et al (16) reported that the expression profile of primary tumors that had metastasized resembled that of metastatic tumors, and that a predictive diagnosis for metastasis was possible based on the analysis of the primary tumor profile. Van't Veer et al (17) also reported that patients with early-stage breast cancer could be classified according to their prognosis based on the gene expression signature obtained from the primary tumors, and specific gene expression profiles were predictive for distant metastases. Thus, the new hypothesis indicates that the acquisition of metastatic ability does not begin in just a few cells in the primary tumor but instead most cells in such tumors are inherently capable of metastasis.
Our hierarchical clustering with the expression profile of the genes closely relevant to the metastatic potential shows that the profile of the metastasized primary tumor resembled one of a metastatic lesion apart from a primary lesion rather than one of a non-metastasized primary tumor. This means that the tumors are segregated according to their final metastatic status rather than their clinical stages. This suggests that the metastatic potential of CRC is not acquired in proportion to cancer progression but has already been encoded in the primary tumor. Thus, our findings support the above new hypothesis rather than the conventional one.
We also succeeded in the verification of this hypothesis using independent primary tumors. Clustering analysis with these genes on CRC samples diagnosed as localized or regional disease allowed the robust classification of metastasized tumors vs non-metastasized tumors. Supervised classification analysis enabled us to predict the postoperative relapse risk of the patients who were diagnosed as localized or regional disease at the time of surgery. The classification appropriately reflected the outcome of CRC patients. Our microarray data provide important information on the metastatic potential in CRC and indicate that the expression profiles in the bulk of primary tumors reflect the character of individual tumors and are possible and valid enough to predict metastasis.
The clinical outcome of patients with CRC is governed to some extent, if not fully, by the inherent character of tumor cells. The programmed expression pattern is detectable in the bulk of primary tumors. The characterization of cancer based on gene expression profile promises to shift the paradigm of cancer diagnosis from general taxonomy by clinicohistopathological parameters to individualized risk assessment.
Currently, because it is clinically difficult to accurately predict metachronous liver metastasis at the time of initial diagnosis, a lot of time and effort is directed toward the detection of asymptomatic recurrences using postoperative monitoring such as CT and the CEA test. Therefore, a more accurate prediction of liver metastasis and clinical outcome should benefit the optimization of cancer treatment, including adjuvant therapy and postoperative surveillance, for individual patients, and at the same time avoid over-or unnecessary treatment and reduce overall cost. Chronological analysis of the gene expression profile should enable a better understanding of the metastatic process. The identified 'interesting' genes and profiles could help design new strategies for the treatment and diagnosis of metastasis.
